Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Sutro Biopharma
Deal Size : Undisclosed
Deal Type : Partnership
VGXI, Sutro Partner to Support Sutro's Clinical Pipeline
Details : The partnership with Sutro Biopharma to support the clinical production of Luvelta (luveltamab tazevibulin), a novel FRα-targeting antibody-drug conjugate for the treatment of ovarian cancer.
Brand Name : Luvelta
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 03, 2024
Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Sutro Biopharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : GT-30,INO-9012,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Geneos Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
VGXI and Geneos Therapeutics Expand Partnership for Personalized Cancer Immunotherapies
Details : Geneos Therapeutics, Inc. has executed a new purchasing contract under their current Clinical Manufacturing Supply Agreement to support the expansion of the ongoing clinical trial for GNOS-PV02.
Brand Name : GNOS-PV02
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 16, 2021
Lead Product(s) : GT-30,INO-9012,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Geneos Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?